Method of modifying isoelectric point of antibody via amino acid substitution in CDR
The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
1. A multispecific antibody comprising a first arm comprising a first heavy chain variable region (VH) and a first light chain variable region (VL) and a second arm comprising a second VH and a second VL, wherein:
the amino acid residue at Kabat numbering position 55 in the first VL is glutamic acid or aspartic acid,
the amino acid residue at Kabat numbering position 55 in the second VL has no charge or has a positive charge; and
the isoelectric point of the first arm is different from the isoelectric point of the second arm.
2. The antibody of claim 1 , further comprising glutamic acid or aspartic acid at Kabat numbering position 31 in the first VH, and an amino acid residue that either has no charge or is positively charged at Kabat numbering position 31 in the second VH.
3. The antibody of claim 1 , wherein the difference between the theoretical isoelectric point of the first arm and that of the second arm is 1.0 or more.
4. The antibody of claim 1 , which is a bispecific antibody that is human or humanized.
5. The antibody of claim 4 , wherein either the first arm or the second arm or both comprise Cλ as a light chain constant region.
6. The antibody of claim 4 , wherein either the first arm or the second arm or both comprise Cκ as a light chain constant region.
7. The antibody of claim 5 , wherein either the first arm or the second arm or both comprise an IgG4 heavy chain constant region.
8. The antibody of claim 1 , wherein one of the two arms binds to Factor IX and the other arm binds to Factor X.
9. A multispecific antibody comprising a first arm comprising a first VH and a first VL and a second arm comprising a second VH and a second VL, wherein:
Kabat numbering positions 61 and 64 in the first VH are both occupied by lysine residues;
Kabat numbering positions 61 and 64 in the second VH are occupied by amino acid residues that either have no charge or are negatively charged; and
the isoelectric point of the first arm is different from the isoelectric point of the second arm.
10. The antibody of claim 9 , further comprising a lysine residue at Kabat numbering position 53 in the first VL, and an amino acid residue that either has no charge or is negatively charged at Kabat numbering position 53 in the second VL.
11. The antibody of claim 9 , wherein the difference between the theoretical isoelectric point of the first arm and that of the second arm is 1.0 or more.
12. The antibody of claim 9 , which is a bispecific antibody that is human or humanized.
13. The antibody of claim 9 , wherein either the first arm or the second arm or both comprise Cλ as a light chain constant region.
14. The antibody of claim 9 , wherein either the first arm or the second arm or both comprise Cκ as a light chain constant region.
15. The antibody of claim 9 , wherein either the first arm or the second arm or both comprise an IgG4 heavy chain constant region.
16. The antibody of claim 11 , wherein one of the two arms binds to Factor IX and the other arm binds to Factor X.
17. A multispecific antibody comprising a first arm comprising a first VH and a first VL and a second arm comprising a second VH and a second VL, wherein:
the amino acid residue at Kabat numbering position 53 in the first VL is lysine;
the amino acid residue at Kabat numbering position 53 in the second VL is uncharged; and
the isoelectric point of the first arm is different from the isoelectric point of the second arm.
18. The antibody of claim 17 , further comprising lysine residues at Kabat numbering positions 61 and 64 in the first VH and uncharged amino acid residues at Kabat numbering positions 61 and 64 in the second VH.
19. The antibody of claim 17 , wherein the difference between the theoretical isoelectric point of the first arm and that of the second arm is 1.0 or more.
20. The antibody of claim 17 , which is a bispecific antibody that is human or humanized.
21. The antibody of claim 20 , wherein either the first arm or the second arm or both comprise Cλ as a light chain constant region.
22. The antibody of claim 20 , wherein either the first arm or the second arm or both comprise Cκ as a light chain constant region.
23. The antibody of claim 20 , wherein either the first arm or the second arm or both comprise an IgG4 heavy chain constant region.
24. The antibody of claim 20 , wherein one of the two arms binds to Factor IX and the other arm binds to Factor X.